Health

ET HealthWorld, Health News, Nisarga Biotech Group, Chairman and CEO, Girish Soman

Shahid Akhter, Editor of ET Healthworld, Greek Soman, Chairman and CEO, Nisarga Biotech Group, learn more about the growing acceptance of Ayurvedic products during a pandemic and the challenges facing clinical trials in Ayurveda.

How is the new era of Ayurvedic brands changing in the D2C market?
Since the new century, the aspirations of the entire community have changed, and the wind of change has begun to blow from the past decade or so. People here in India and the West are beginning to talk about using Ayurvedic herbs as a preventative measure for health care, rather than just using modern medicine. The onset of the Covid-19 pandemic has significantly accelerated the number of such consumers. Apart from the benefits of classic Ayurvedic textbooks, these consumers are looking for cleaner natural products, more transparent disclosures, and validated scientific data.

Consumers are willing to pay for proper quality and effectiveness, as well as the brand name associated with the product. More culturally creative consumers treat employees, suppliers, and other stakeholders fairly, whether companies follow ethical practices in acquiring raw materials, whether they follow ethical business practices, and I’m looking to see if there is. This is a welcome change and has the potential to grow the Indian D2C-focused corporate market. The digital revolution in handheld devices has the potential to steadily maintain an upward trend over the next 20 years.

With so many Ayurvedic brands investigating and investing in Covid clinical trials, how are the Nisarga & AIIA clinical trials planning to break the turmoil? From a R & D perspective, what are your previous trial investments and your brand’s future investments?

There were shades and screams about the huge funding to develop the vaccine at record speed. Most vaccine candidates were funded by large venture capital funds or even governments around the world. In India as well, the government has actively funded and promoted vaccine research. However, this agility was not observed in Ayurvedic studies. Many large Ayurvedic companies have succeeded in conducting their own trials in a small patient population rather than adopting a double-blind, randomized trial methodology. Most of these trials are aimed at “treating Covid-19 patients” by combining both symptomatic and Ayurvedic medications, and studies conducted to prevent Covid-19 infection It was very few.

In contrast, the Nisarga study is based on a patent-pending extract of neem leaves, which has been well studied in preclinical studies by reputable US research institutes for six years and is toxic according to US FDA standards. The study is complete. This double-blind randomized trial, conducted to prevent Covid-19, was wholly funded by Nisarga Biotech and conducted by the All India Institute of Ayurveda in New Delhi in collaboration with ESI Fospital Faridabad.

The study was conducted in 200 subjects to confirm the prophylactic effect of neem leaf extract capsules of Nisarga in subjects in contact with Covid-19 patients. Neem has been reported to have anti-inflammatory, antibacterial / antiviral and antioxidant properties and may be used as a Covid-19 prophylaxis. This signal exploration study shows very promising results that have been thoroughly analyzed by researchers, with the final results expected within the next two weeks. The notable fact is that side effects are mild to moderately severe and are well resolved with or without medication.

Has the investment interest of domestic and multinational pharmaceutical brands soared in the Ayurvedic medicine or wellness sector since the pandemic?
Sadly, in our country it is not possible to obtain patent protection for claims on how to use such herbal products. This will prevent individual investors from investing in such research. You can also emulate a product without worrying about product quality or standardizing the product. In this pandemic situation, the main motivation for investing in this study is to demonstrate the usefulness and safety of the patent-pending extract. By doing so, you can bring together foreign buyers and investors as well as governments to invest more money for large-scale testing on thousands of subjects.

This should be taken seriously by experts in the field of Ayurveda and modern medicine, given the near-vaccine success rate (currently reported to be 60%). At a press conference on September 23, 2020, Dr. Bhargava, Head of ICMR, said, “We are aiming for 100% effectiveness, but it can reach 50% to 100%, but still. It will be an effective vaccine against viruses. “

After demonstrating the effectiveness of the drug in a government-funded gold standard clinical trial in a public-private partnership, our prestigious Prime Minister has brought it to the world by adopting Ayurvedic ancient science to the masses. You need to seize this opportunity to introduce your return on investment.

What are the sales practices or marketing insights you can adopt to maintain momentum in the last quarter of the fiscal year?
This pandemic creates a new normal, recognizing that everyone in society must focus on preventive medical measures rather than just taking medication. We will continue our efforts to convey knowledge and raise awareness among the public about the importance of using herbal solutions available using ancient knowledge and cutting-edge research. We will introduce our research to consumers and continue to educate them on how to manage their daily lives with naturally available options.

What are your future plans?
Nisarga plans to continue research and development of purified neem leaf extract for use in cancer patients suffering from head and neck cancer and colorectal cancer. The company has completed cell line research, preclinical animal research, and patent filling of neem purified extracts rich in nimbolide and two other markers. The company completed most of the research work to create a data pack for submitting IND applications in the United States through a US subsidiary in about a year. This will increase the value of your IP many times over.

Creating an anti-cancer drug that goes through Phase I and Phase II Phase III costs $ 300 to $ 400 million in pharmaceutical companies and a 10-year period. Nisarga believes that IP can be used to significantly reduce this investment and significantly shorten the timeline. Therefore, Nisarga is making a big bet on this project and is partnering with Nisarga, who has the ability to further fund this study, to use its US subsidiary to share the benefits of this study in the long run. We are looking for a drug development or partnership with a pharmaceutical company of interest.



ET HealthWorld, Health News, Nisarga Biotech Group, Chairman and CEO, Girish Soman

Source link ET HealthWorld, Health News, Nisarga Biotech Group, Chairman and CEO, Girish Soman

Related Articles

Back to top button